ALK and neoplasm: The assessment of CTCs to determine EGFR mutation status, ALK rearrangements and PD-L1 status lends itself to the identification of patients for targeted therapies, be they oncogenic or immune-related, in patients where tumour biopsy tissue may not be available [30,31,32].